{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:15Z","timestamp":1760188995794},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.tmrv.2008.02.007","type":"journal-article","created":{"date-parts":[[2008,6,21]],"date-time":"2008-06-21T08:30:11Z","timestamp":1214037011000},"page":"177-187","source":"Crossref","is-referenced-by-count":18,"title":["Evidence for the Use of Recombinant Factor VIIa in the Prevention and Treatment of Bleeding in Patients Without Hemophilia"],"prefix":"10.1016","volume":"22","author":[{"given":"Janet","family":"Birchall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J.","family":"Doree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2008.02.007_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI110939","article-title":"Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors","volume":"71","author":"Hedner","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2008.02.007_bib2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(88)90259-0","article-title":"Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy","volume":"2","author":"Hedner","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2008.02.007_bib3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2008.02.007_bib4","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2008.02.007_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/14779072.2.5.661","article-title":"Recombinant factor VIIa: Clinical applications for an intravenous hemostatic agent with broad-spectrum potential","volume":"2","author":"Carr","year":"2004","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.tmrv.2008.02.007_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00005373-200104000-00021","article-title":"Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries","volume":"50","author":"Martinowitz","year":"2001","journal-title":"J Trauma"},{"key":"10.1016\/j.tmrv.2008.02.007_bib7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(99)05155-7","article-title":"Treatment of traumatic bleeding with recombinant factor VIIa","volume":"354","author":"Kenet","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.tmrv.2008.02.007_bib8","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1186\/cc3783","article-title":"Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings","volume":"9","author":"Grounds","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.tmrv.2008.02.007_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation-2006.1.426","article-title":"Challenges in the therapeutic use of a \u201cso-called\u201d universal hemostatic agent: Recombinant factor VIIa","author":"Hoots","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"10.1016\/j.tmrv.2008.02.007_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1778-428X.2006.00033.x","article-title":"Use of recombinant activated factor VII in the management of medical and surgical bleeding: A critical review","volume":"8","author":"Steiner","year":"2006","journal-title":"Transfus Alternatives Transfus Med"},{"key":"10.1016\/j.tmrv.2008.02.007_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1423-0410.2006.00888.x","article-title":"Recombinant-activated coagulation factor VIIa (NovoSeven): Current development","volume":"92","author":"Weiskopf","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2008.02.007_bib12","first-page":"CD005011","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","volume":"2","author":"Stanworth","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2008.02.007_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH04-03-0163","article-title":"The use or rFVIIa in non-haemophilia bleeding contitions in paediatrics: A systematic review","volume":"92","author":"Mathew","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2008.02.007_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.CCM.0000159087.85970.38","article-title":"Efficacy and safety or recombinant factor VIIa for treatment of severe bleeding: A systematic review","volume":"33","author":"Levi","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2008.02.007_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2008.02.007_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.tmrv.2008.02.007_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TA.0000171453.37949.B7","article-title":"Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials","volume":"59","author":"Boffard","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.tmrv.2008.02.007_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/gast.2002.34164","article-title":"Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy","volume":"123","author":"Jeffers","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tmrv.2008.02.007_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","article-title":"Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial","volume":"361","author":"Friederich","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2008.02.007_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00000542-200502000-00006","article-title":"Recombinant coagulation factor VIIa in major liver resection: A randomized, placebo-controlled, double-blind clinical trial","volume":"102","author":"Lodge","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tmrv.2008.02.007_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.amjsurg.2005.10.019","article-title":"Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"191","author":"Shao","year":"2006","journal-title":"Am J Surg"},{"key":"10.1016\/j.tmrv.2008.02.007_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.20470","article-title":"Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation","volume":"11","author":"Lodge","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.tmrv.2008.02.007_bib23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/lt.20458","article-title":"Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease","volume":"11","author":"Planinsic","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.tmrv.2008.02.007_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/bja\/ael205","article-title":"Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage","volume":"97","author":"Bowles","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.tmrv.2008.02.007_bib25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/bja\/aei102","article-title":"Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery or traumatic fracture of pelvis or pelvis and acetabulum: A double-blind, randomized, placebo-controlled trial","volume":"94","author":"Raobaikady","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.tmrv.2008.02.007_bib26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/bja\/aei244","article-title":"Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study","volume":"95","author":"Diprose","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.tmrv.2008.02.007_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mbc.0000233369.03358.c1","article-title":"Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy","volume":"17","author":"Ekert","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2008.02.007_bib28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.gastro.2004.07.015","article-title":"Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tmrv.2008.02.007_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.mbc.0000186837.78432.2f","article-title":"Control of bleeding in children with dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study","volume":"16","author":"Chuansumrit","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2008.02.007_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/01.STR.0000149628.80251.b8","article-title":"Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage","volume":"36","author":"Mayer","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.tmrv.2008.02.007_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1385\/NCC:4:3:206","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage. US phase IIA trial","volume":"4","author":"Mayer","year":"2006","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.tmrv.2008.02.007_bib32","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1538-7836.2005.01523.x","article-title":"Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation","volume":"3","author":"Pihusch","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2008.02.007_bib33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant activated factor VII for acute intracerebral hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2008.02.007_bib34","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/cc5026","article-title":"Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding\u2014A European perspective","volume":"10","author":"Vincent","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.tmrv.2008.02.007_bib35","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1537-2995.2005.00548.x","article-title":"A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes","volume":"45","author":"MacLaren","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2008.02.007_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.2007.06621.x","article-title":"Use of recombinant activated factor VII in the management of intractable haemorrhage: A survey of current UK practice","volume":"138","author":"Biss","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2008.02.007_bib37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2008.02.007_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1538-7836.2005.01203.x","article-title":"Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force","volume":"3","author":"Martinowitz","year":"2005","journal-title":"J Throm Haemost"},{"key":"10.1016\/j.tmrv.2008.02.007_bib39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1538-7836.2004.00909.x","article-title":"Recombinant factor VIIa: A general hemostatic agent? Yes","volume":"2","author":"Roberts","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2008.02.007_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0885066605285223","article-title":"Off-label reports of new biologics: Exciting new therapy or dubious research? Examples from recombinant activated factor VII","volume":"21","author":"Dzik","year":"2006","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.tmrv.2008.02.007_bib41","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0020138","article-title":"Medical journals are an extension of the marketing arm of pharmaceutical companies","volume":"2","author":"Smith","year":"2006","journal-title":"PloS Med"},{"key":"10.1016\/j.tmrv.2008.02.007_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.ta.0000196343.14187.fd","article-title":"Randomized trials in patients with blunt and penetrating trauma","volume":"60","author":"Webert","year":"2006","journal-title":"J Trauma"},{"key":"10.1016\/j.tmrv.2008.02.007_bib43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.amjsurg.2005.03.034","article-title":"Are we giving enough coagulation factors during major trauma resuscitation?","volume":"190","author":"Ho","year":"2005","journal-title":"Am Journal Surg"},{"key":"10.1016\/j.tmrv.2008.02.007_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1212\/01.wnl.0000275280.58475.45","article-title":"Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa","volume":"69","author":"Mayer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.tmrv.2008.02.007_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2008.02.007_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/TA.0b013e318031afc2","article-title":"Thromboembolic complications associated with factor VIIa administration","volume":"62","author":"Thomas","year":"2007","journal-title":"J Trauma"},{"key":"10.1016\/j.tmrv.2008.02.007_bib47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/bja\/aei103","article-title":"Is recombinant FVIIa the magic bullet in the treatment of major bleeding?","volume":"94","author":"Spahn","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.tmrv.2008.02.007_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early treatment with recombinant factor VIIa results in greater efficacy with less product","volume":"61","author":"Lusher","year":"1998","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.tmrv.2008.02.007_bib49","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.0041-1132.2003.00633.x","article-title":"Recombinant FVIIa for intractable hemorrhage: more questions than answers","volume":"43","author":"Key","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2008.02.007_bib50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3171\/jns.2002.97.4.0771","article-title":"Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study","volume":"97","author":"Hillman","year":"2002","journal-title":"J Neurosurg"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796308000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796308000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T07:49:19Z","timestamp":1557647359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796308000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0887796308000126"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2008.02.007","relation":{},"ISSN":["0887-7963"],"issn-type":[{"type":"print","value":"0887-7963"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}